Avails Medical’s eQUANT™ system submitted to FDA for 510(k) clearance
MENLO PARK, Calif., June 12, 2023 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) solutions announced today the submission of its eQUANT™…
Read More
Avails Medical awarded additional $1.7M in CARB-X funding for the development of its rapid antibiotic susceptibility testing device to identify the most effective antibiotic therapy
MENLO PARK, Calif., Sept. 1, 2022 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated, and fully electrical antibiotic susceptibility testing (eAST™) announced today the transition to the next phase…
Read More
Avails Medical announces the commencement of U.S. Pivotal Clinical Trials for eQUANT™
MENLO PARK, Calif. , Aug. 15, 2022 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (eAST™) announced today the commencement of U.S. pivotal clinical…
Read More
Avails Medical’s eQUANT paper ‘Novel electronic biosensor for automated inoculum preparation to accelerate antimicrobial susceptibility testing’ published in Scientific Reports
MENLO PARK, Calif., June 1, 2021 /PRNewswire/ – Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) announced today the publication of a new peer-reviewed paper…
Read More
EVENTS
ECCMID 2023
April 15-18
Copenhagen, Denmark
Booth B5-04
ASM Microbe 23
June 15-19
Houston, Texas